-In July, PersonGen Announces CDE Clearance of IND Application for TAA06, A First-in-Class CAR-T Cell Therapy Targeting B7-H3, for the Treatment of Patients with R/R Neuroblastoma

-In June, PersonGen Completed the Fully Automated CAR-T cell Industrialization Base in Hefei High-Tech Zone 

-In May, PersonGen Presided over the Development of Major Special Projects of Science and Technology in Anhui Province

-In April, PersonGen Announced the Infusion of First Patient Enrolled in the Phase I Clinical Trial Evaluating PA3-17

-In April, PersonGen Announced the Acceptance of IND Application of B7-H3 CAR-T (TAA06 Injection) by CDE

-In March, TAA06 Was Granted FDA ODD and RPD for the Treatment of Neuroblastoma

-In January, PersonGen Completed the B Round of Financing Led by Zhongjin Qide and Huatai Zijin, and Co-invested by Panyi Capital and Huatong Capital.

-In December, PersonGen Won the Outstanding Project Award of 2021 National Breakthrough Technology Innovation Competition

-In December, PersonGen Won the Designation of 2021 Hefei High Growth Seed Enterprise

-In November, PersonGen Won the Young Eagle Enterprise Designation of Hefei High-tech Zone in 2021

-In November, PA3-17 Was Granted ODD by US FDA

-In October, PersonGen Won the Annual Award of 2021 China Bioinnovative Drugs with the Most Growth Potential

-In September, PersonGen Invested to Set Up a Subsidiary in Shandong

-In August, PersonGen Announced the Acceptance of IND Application of PA3-17, the Globally First Autologous CD7 CAR-T

-In June, Dr. Yang Lin Was Awarded the Top 10 Drug Innovation Scientists of 2020

-In May, PersonGen Completed A Round of Financing Led by Yuansheng Venture Capital, with Puen Guoxin Equity Investment and Xiantong Capital.

-In April, PersonGen Invested and Established PersonGen BioPharmaceutical (Shijiazhuang) Co., LTD.

-In March, PersonGen Won the Second Prize of Anhui Province Science and Technology Award.

-In March, After the Completion of a Major Internal Restructuring, PersonGen Became a Wholly-Owned Subsidiary of PersonGen Group.

-In December, PersonGen Won the Young Eagle Enterprise Designation of Hefei High-tech Zone in 2020

-In December, Development of Allogeneic UCAR-γδT Cell Platform

-In October, Development of iPSC-induced UCAR-NK/T Cell Preparation Platform

-In August, IND Application for Multiple First-in-Class CAR-T Products

-In December, PersonGen Won the Deep Cultivation Award of Cell Therapy Enterprise

-In December, PersonGen Was Awarded the Listed Nursery Enterprise

-In December, PersonGen Built a Clinical-Grade Lentivirus Suspension Preparation Technology Platform 

-In December, PersonGen Announced the Clearance of IND Application of CD19 CAR-T by CDE

-In November, PersonGen Won the National High-Tech Enterprise

-In September, PersonGen Developed Autologous CD7 CAR-T

-In June, PersonGen Developed CD7-CAR-NK

-In April, Lin YANG Was Awarded the Leading Entrepreneurial Talent of Hefei

-In March, PersonGen Participated in the Cooperative Development of Key Research and Development Projects in Anhui Province

-In March, Dr. Yang Lin Won the Award of Excellent Paper

-In February, PersonGen Made Major Clinical Progress in CD19 CAR-T and BCMA CAR-T

-In December, PersonGen Participated in the Cooperative Research and Development of Major Science and Technology Special Projects in Anhui Province

-In October, Lin YANG Was Awarded the Title of Technical Leader in Anhui Province

-In June, PersonGen Built Off-the-shelf γδT Cell Preparation Platform

-In February, PersonGen Was Awarded as 2017 Outstanding Enterprise of Hefei High-Tech Zone and "Talent Attraction Award"

-In February, PersonGen Won the Designation of Hefei Luzhou Industrial Innovation Team

-In January, PersonGen Built China's First Fully Automated CAR-T Cell Preparation Platform

-In December, PersonGen Won the Second Prize of China Innovation and Entrepreneurship Competition

-In November, PersonGen Won the First Prize of "Create Sound in China" in Anhui Province Innovation and Entrepreneurship Competition

-In October, PersonGen Bulit Semi-automatic Modular CAR-T Preparation Process

-In September, PersonGen Completed Clinical-Grade Plasmids and Lentiviral Cell Processes

-In December, PersonGen Invested 100 million yuan to Establish Industrialization Base (PersonGen Anke Cell Technology Co., LTD.) in Hefei High-Tech Zone 

-In November, PersonGen Undertook the Research and Development of Sub-Topics of National Key Research and Development Programs

-In November, PersonGen Won the Designation of National High-Tech Enterprise

-In September, PersonGen Was Rated as "Six Talent Peak" High-Level Talent Team

-In June, the Structure, Function and Activity Verification Platform of CAR was Successfully Constructed

-In November, PersonGen Conducted the Clinical Trial of Globally First MUC1 CAR-T Against Solid Tumors

-In November, PersonGen Conducted the Clinical Trial of Globally First CAR-T with Multiple Targets

-In March, PersonGen Won the Advanced Technology Service Enterprise

-In January, PersonGen Obtained Anke's Investment

-In November, PersonGen Developed the PD-1 Blocking Antibody 

-In June, PersonGen Developed the CD7 Nanobody

-In March, PersonGen Built NK Cell Preparation Platform

-In December, PersonGen Was Awarded ISO9001: 2008 Quality Management System Certification

-In October, Lin YANG Was Awarded the High-Level Entrepreneurship Talent of Jiangsu Province

-In June, PersonGen Built the Bi-Specific CAR-T Technology Platform

-In May, PersonGen Was Approved to Set Up the Enterprise Postdoctoral Incubation Station in Suzhou Industrial Park

-In December, PersonGen Built Nano-Antibody Screening Platform

-In October, PersonGen Was Approved to Set Up Suzhou Tumor Immunological Diagnosis and Treatment Engineering Technology Research Center

-In August, PersonGen Obtained Angel Round Investment from Zhongxin Venture Capital

-In July, PersonGen Won the Jiangsu Province Private Science and Technology Enterprise

-In July, Lin YANG Was Awarded the Gusu Leading Talent of Innovation and Entrepreneurship 

-In March, PersonGen Built 2nd and 3rd Generation CAR-T Technology Platform

-In December, PersonGen Built in vivo T Cell Preparation Technology Platform.

-In October, PersonGen Was Awarded Member of Jiangsu Innovation Team.

-In December, Lin YANG Was Awarded the Leading Talent in Science and Technology of Suzhou Industrial Park.

-In May, the Company Was Registered and Established in Suzhou Industrial Park.